Company intelligence / Profile preview

Turn Therapeutics

Calabasas/Westlake Village, California, United Statesturntherapeutics.com ↗

Ownership: Public · TTRX
Employees: ~7
Development stage: Commercial

Overview

Turn Therapeutics has an FDA-cleared antimicrobial ointment (Hexagen) with over 200,000 patient uses and zero reported adverse events. The company is now pursuing clinical trials for new drug indications including eczema and onychomycosis.

Therapeutic areas: EndocrinologyDermatologyInfectious Diseases
Modalities: Topical formulationsOil suspension technology
Industry: Biotech

Drug pipeline

3 assets

Hexagen

2 more assets in the full pipeline.

Request access →

Partnerships

MiMedx (licensing deal worth up to $70M+)GEM Global Yield LLC SCS ($75M investment commitment)

Financials

Market cap: $377.1M
Total revenue: $0
Enterprise value: $372.9M

Beyond the preview

Go deeper on Turn Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Turn Therapeutics.

Explore the full profile